에스토니아 - 에스토니아어 - Ravimiamet

actavis group ptc ehf. - losartaan+hüdroklorotiasiid - õhukese polümeerikattega tablett - 100mg+25mg 98tk; 100mg+25mg 28tk; 100mg+25mg 60tk; 100mg+25mg 14tk; 100mg+25mg 56tk; 100mg+25mg 50tk; 100mg+25mg 500tk

에스토니아 - 에스토니아어 - Ravimiamet

emergent operations ireland limited - naloksoon - ninasprei, lahus üheannuselises konteineris - 3,6mg 0.1ml 0.1ml 2tk

에스토니아 - 에스토니아어 - Ravimiamet

emergent operations ireland limited - naloksoon - ninasprei, lahus üheannuselises konteineris - 1,8mg 0.1ml 0.1ml 2tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud viii faktori puudulikkus). iblias võib kasutada kõikides vanuserühmades.

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofiilia a. - antihemorraagilised ained - verejooksu ravi ja profülaktika hemofiilia a patsientidel (kaasasündinud faktor viii puudulikkus). see preparaat ei sisalda von willebrand faktori ja ei ole seega näidustatud von willebrand ' s disease.

에스토니아 - 에스토니아어 - Ravimiamet

actavis group ptc ehf. - desloratadiin - suus dispergeeruv tablett - 5mg 90tk; 5mg 60tk; 5mg 20tk; 5mg 5tk; 5mg 10tk; 5mg 6tk; 5mg 18tk; 5mg 15tk; 5mg 30tk; 5mg 50tk

에스토니아 - 에스토니아어 - Ravimiamet

actavis group ptc ehf. - desloratadiin - suus dispergeeruv tablett - 2,5mg 10tk; 2,5mg 5tk; 2,5mg 12tk; 2,5mg 50tk; 2,5mg 60tk; 2,5mg 30tk; 2,5mg 20tk; 2,5mg 100tk; 2,5mg 6tk; 2,5mg 15tk

유럽 연합 - 에스토니아어 - EMA (European Medicines Agency)

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastilised ained - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.